DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.
>>5 Stocks Set to Soar on Bullish Earnings
Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.
10 Best Valued Stocks To Own Right Now: Texas Capital Bancshares Inc.(TCBI)
Texas Capital Bancshares, Inc. operates as the holding company for Texas Capital Bank, National Association that provides various banking products and services for commercial and high net worth customers in Texas. It primarily engages in generating deposits and originating loans. The company?s deposit products include consumer checking accounts, savings accounts, money market accounts, and certificates of deposit, as well as commercial checking accounts, lockbox accounts, cash concentration accounts, and other treasury management products. Its lending products portfolio comprises commercial loans and leases; real estate loans, including loans secured by properties, and temporary financing for commercial and residential property; construction loans consisting of single-family residential properties and commercial projects; loans held for sale; and letters of credit. The company also provides trust and wealth management services, including investment management, personal tr ust and estate services, custodial services, retirement accounts, and related services, as well as offers retirement products, including individual retirement accounts and administrative services for retirement vehicles, such as pension and profit sharing plans. Texas Capital Bancshares, Inc. has banking offices in Dallas, Houston, Fort Worth, Austin, San Antonio, and the Cayman Islands. As of December 31, 2010, it conducted business at nine full service banking locations and one operations center. The company was founded in 1996 and is headquartered in Dallas, Texas.
Advisors' Opinion:- [By John Udovich]
Texas has set another record for job creation�with small cap Texas banking stock like Texas Capital Bancshares (NASDAQ: TCBI), ViewPoint Financial Group (NASDAQ: VPFG) and First Financial Bankshares (NASDAQ: FFIN) naturally being well positioned to take advantage of the Texas economic miracle (see my previous article: Texas is Booming and So Are These Texas Stocks (EE, TPL & ATO)). I should�add that I wrote about�these Texas banking stocks back in late 2012�(see: Don�� Mess With Texas Banking Stocks TCBI, VPFG & FFIN) and the Texas Workforce Commission has just�reported that the Texas economy added 36,400 jobs in September while over the past 12 months, employers added 413,700 jobs ��the most ever recorded by the state. Moreover, several companies surveyed by the Dallas Fed responded by saying�they are seeing labor market tightness�while companies are saying they are experiencing upward wage pressures�and�staffing�firms�note that�candidates are often receiving multiple offers.
- [By Charley Blaine]
Also in the list: Bank of America (NYSE: BAC), up 13.31 percent; Citigroup (NYSE: C), up 8.8 percent; U.S. Bancorp (NYSE: USB), up 5.33 percent; and Texas Capital Bancshares (NASDAQ: TCBI) up 8.18 percent.
5 Best Forestry Stocks To Watch For 2014: RealPage Inc.(RP)
RealPage, Inc. provides on demand software solutions for the rental housing industry in North America. It offers property management systems, including OneSite to manage leasing and rents, facilities, purchasing, accounting, budgeting, and living of multi-family, housing and urban development (HUD), tax credit, privatized military housing, and student housing; and Propertyware for accounting, maintenance and work order management, marketing spend management, and portal services, as well as screening, renter?s insurance, and payment solutions. The company also provides on premise property management systems that include RentRoll for small conventional apartment communities; HUD Manager for small HUD, rural housing services, and tax credit subsidized apartment communities; Tenant Pro for small conventional properties; Spectra, an apartment and commercial modular property management system; and i-CAM and Management Plus property management software that automates and streaml ines rental activities. In addition, it offers software-enabled value-added services, such as LeaseStar, a system that manage marketing and leasing operations and enable owners and managers to originate, capture, track, manage, and close leads; YieldStar, a scientific yield management system, which enables owners and managers to optimize rents; LeasingDesk, a risk mitigation system to reduce delinquency, liability, and property damage risk; and Velocity that offers billing and utility management services; OpsTechnology that offers spend management systems that enable owners and managers to control costs; shared cloud services, which are integrated with property management systems and software-enabled valued added services; and RealPage Senior Living, an integrated care management, community management, and marketing management platform. The company sells its software and services directly through its sales force. RealPage, Inc. is headquartered in Carrollton, Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on RealPage (Nasdaq: RP ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on RealPage (Nasdaq: RP ) , whose recent revenue and earnings are plotted below.
5 Best Forestry Stocks To Watch For 2014: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Maxx Chatsko]
The astounding rise of Pharmacyclics (NASDAQ: PCYC ) through the markets has been largely based on its BTK inhibitor ibrutinib, which is being evaluated in four types of blood cancers and in a preclinical study for autoimmune indications. The rise is no fluke, either. Ibrutinib has shown very promising results in two phase 2 trials as a monotherapy and will soon be moved to phase 3 trials for both. With billions of dollars between the lymphoma and autoimmune markets up for grabs, it is easy to see why shares have risen 2,000% since the company acquired its lead drug candidate in 2006. Can Celgene tap into this multibillion opportunity with CC-292? Ask me again in about five years.�
- [By Brian Orelli]
Imbruvica, which Johnson & Johnson developed with Pharmacyclics (NASDAQ: PCYC ) , is already approved in the U.S. to treat mantle cell lymphoma and chronic lymphocytic leukemia. The duo is also testing the drug in diffuse large B-cell lymphoma, multiple myeloma, follicular lymphoma, and Waldenstrom's macroglobulinemia.
- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the - [By Jon C. Ogg]
Pharmacyclics Inc. (NASDAQ: PCYC) was started as Overweight with a $142 price target at J.P. Morgan. Deutsche Bank also started it with a Buy rating and a $170 price target.
5 Best Forestry Stocks To Watch For 2014: Tootsie Roll Industries Inc.(TR)
Tootsie Roll Industries, Inc. engages in the manufacture and sale of confectionery products primarily in the United States, Canada, and Mexico. The company sells its products under the TOOTSIE ROLL, TOOTSIE ROLL POPS, CHILD?S PLAY, CARAMEL APPLE POPS, CHARMS, BLOW-POP, BLUE RAZZ, ZIP-A-DEE POPS, CELLA?S, MASON DOTS, MASON CROWS, JUNIOR MINT, CHARLESTON CHEW, SUGAR DADDY, SUGAR BABIES, ANDES, FLUFFY STUFF, DUBBLE BUBBLE, RAZZLES, CRY BABY, and NIK-L-NIP. It distributes its products through candy and grocery brokers to the wholesale distributors of candy and groceries, supermarkets, variety stores, dollar stores, chain grocers, drug chains, discount chains, cooperative grocery associations, warehouse and membership club stores, vending machine operators, and the U. S. military and fund-raising charitable organizations. The company was founded in 1896 and is based in Chicago, Illinois.
Advisors' Opinion:- [By Rich Smith]
At the same time, tiny Tootsie Roll (NYSE: TR ) may see its sales grow as little as 13% through 2016. Could it be that in the candy industry, bigger is better? Does Hershey lack the scale to compete effectively against mammoth Mondelez?
No comments:
Post a Comment